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Anticancer
Organo-rhodiumOrganometallic complexes have the potential to behave as catalytic drugs.We investigate here Rh(III) complexes
of general formula [(Cpx)Rh(N,N′)(Cl)], where N,N′ is ethylenediamine (en), 2,2′-bipyridine (bpy), 1,10-
phenanthroline (phen) or N-(2-aminoethyl)-4-(triﬂuoromethyl)benzenesulfonamide (TfEn), and Cpx is
pentamethylcyclopentadienyl (Cp*), 1-phenyl-2,3,4,5-tetramethylcyclopentadienyl (CpxPh) or 1-biphenyl-
2,3,4,5-tetramethyl cyclopentadienyl (CpxPhPh). These complexes can reduce NAD+ to NADH using formate
as a hydride source under biologically-relevant conditions. The catalytic activity decreased in the order of N,N-
chelated ligand bpy N phen N enwith Cp* as the η5-donor. The en complexes (1–3) becamemore active with ex-
tension to the CpX ring, whereas the activity of the phen (7–9) and bpy (4–6) compounds decreased.
[Cp*Rh(bpy)Cl]+ (4) showed the highest catalytic activity, with a TOF of 37.4 ± 2 h−1. Fast hydrolysis of the
chlorido complexes 1–10 was observed by 1H NMR (b10 min at 310 K). The pKa* values for the aqua adducts
were determined to be ca. 8–10. Complexes 1–9 also catalysed the reduction of pyruvate to lactate using formate
as the hydride donor. The efﬁciency of the transfer hydrogenation reactionswas highly dependent on the nature
of the chelating ligand and the Cpx ring. Competition reactions betweenNAD+ and pyruvate for reduction by for-
mate catalysed by 4 showed a preference for reduction of NAD+. The antiproliferative activity of complex 3 to-
wards A2780 human ovarian cancer cells increased by up to 50% when administered in combination with non-
toxic doses of formate, suggesting that transfer hydrogenation can induce reductive stress in cancer cells.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Transfer hydrogenation reactions for the reduction of ketones, imines
or C_C double bonds have been intensively studied in recent years [1–4].
Precious metal complexes containing Ru, Rh or Ir are often effective as
transfer hydrogenation catalysts, and half-sandwich organometallic com-
plexes in particular have achieved high conversions, turnover frequencies
(TOF) and enantio-selectivities [1–4]. Ruthenium(II) catalysts are often
themost efﬁcient, partly due to their slower rate of ligand exchange com-
pared to Rh(III) or Ir(III), which, in many cases, provides higher chemo-
and enantio-selectivity [1–3,5–7]. Although rhodium catalysts can be
more active, this can be accompanied by a loss of chemo- and enantio-
selectivity. Nevertheless, catalytic activity and enantio-selectivity depend
on the choice of appropriate chiral ligands, on the substrate, the hydride
donor, and on the reaction conditions [1–3,5–7].
There is current interest in metal-based complexes capable of
catalysing reactions in cells [8–11].Metallodrugswith catalytic properties
can potentially be administered in smaller doses consequently leading to
lower toxicity [8–11]. Transfer hydrogenation reactions have attracted. This is an open access article undermuch attention for the reduction of molecules inside cells [8–11].
Organo-Ru(II) and -Ir(III) complexes can catalyse hydride transfer reac-
tions under biologically-relevant conditions (pH 7.2, 310 K, aqueous
media) [12–17]. For example, [(η6-arene)Ru(bipyrimidine)Cl]+ or [(Cp-
xIr(phenanthroline)Cl]+ where CpX is pentamethylcyclopentadienyl
(Cp*), 1-phenyl-2,3,4,5-tetramethylcyclopentadienyl (CpxPh) or 1-
biphenyl-2,3,4,5-tetramethylcyclopentadienyl (CpxPhPh) can utilise re-
duced nicotamide adenine dinucleotide (NADH) to transfer hydride and
reduce biomolecules such as pyruvate [13,14]. The transfer of hydride to
nicotinamide adenine dinucleotide (NAD+) can also be achieved using
formate as an hydride source, [(η6-(arene)Ru(ethylendiamine)Cl]+ and
[(η6-(arene)Ru(N-(2-aminoethyl)-sulfonamide)Cl]+ where arene = p-
cymene (p-cym), benzene (bn), hexamethyl benzene (hmb) or
biphenyl (bip) [12,15,16].
Our recent work suggests that transfer hydrogenation catalysed by
organometallic complexes can be achieved inside cells [12,13]. For ex-
ample, the Ir(III) complex [(Cpxphph)Ir(phenylpyrdine)py]+, where py
is pyridine, can utilise NADH as a biological hydride donor, to generate
an iridium-hydride complex. The hydrido complex is able to transfer
hydride to molecular oxygen, increasing the levels of hydrogen
peroxide and reactive oxygen species in cancer cells [13]. Also, the
Ru(II) complex [(p-cym)Ru(TsEn)Cl] where TsEn is N-(2-aminoethyl)-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cancer cells when co-administered with sodium formate, potentiating
the anti-cancer activity of the complex [12].
The aim of the present work was to synthesise a series of Rh(III) Cp*
catalysts which can carry out transfer hydrogenation reactions in cells.
Half-sandwich complexes of the type [(CpXRh(N,N’)Cl]n+, where N,N′=
ethylenediamine (en), 2,2′-bipyridine (bpy), 2,2′-dimethylbipyridine
(mbpy) and 1,10-phenanthroline (phen) were synthesised and fully
characterised (Fig. 1). The activity of these Rh(III) complexes for the re-
duction of NAD+ in the presence of formate was compared with their
Ru(II) analogues [(η6-arene)Ru(en)Cl] and [(η6-arene)Ru(TsEn)Cl]. We
also studied the reduction of pyruvate to lactate via hydride transfer
from formate, a process carried out naturally in vivo by the enzyme lactate
dehydrogenase and the coenzyme NADH. Finally, the antiproliferative
activity of the complexes towards cancer cells in the presence of excess
formate was also investigated.
2. Experimental
2.1. Materials
Rhodium(III) trichloride hydrate was purchased from PreciousMetals
Online (PMO Pty Ltd.) and used as received. Ethylenendiamine (en) was
purchased from Sigma-Aldrich and freshly distilled prior to use. The
protonated ligands 3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene
(HCpXPh) and 3-biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene
(HCpxPhPh) were synthesised following the methods in the literature
[18,19]. The Rh(III)-arene precursor dimers [(Cpx)RhCl2]2 were
prepared following literature methods [20], as was the ligand N-(2-
aminoethyl)-4-(triﬂuoromethyl)benzenesulfonamide (TfEnH) [15].
2,2′-Bipyridine, 4,4′-dimethyl-2,2′-dipyridine, 1,10-phenanthroline, 4-
bromo-biphenyl, 4-bromo-biphenyl, 1.6 M n-butyllithium in hexane,
phenyllithium in ether (1.8 mM), 2,4-pentamethylcyclopentadiene,
2,3,4,5-tetramethyl-2-cyclopentanone were obtained from Sigma-
Aldrich. Magnesium sulphate, ammonium hexaﬂuorophosphate, silver
nitrate, potassium hydroxide, sodium chloride, hydrochloric acid were
obtained from Fisher Scientiﬁc. Sodium formate, perchloric acid, β-
nicotinamide adenine dinucleotide hydrate (NAD+), β-nicotinamide
adenine dinucleotide reduced disodium salt (NADH) and sodium pyru-
vate were purchased from Sigma-Aldrich. DMSO-d6, MeOD-d4, D2O,
(CD3)2CO-d6 and CDCl3 for NMR spectroscopy were purchased from
Sigma-Aldrich and Cambridge Isotope Labs Inc. Non-dried solvents
used in syntheses were obtained from Fisher Scientiﬁc and Prolabo.
2.2. NMR spectroscopy
1HNMR spectrawere acquired in 5mmNMR tubes at 298K or 310K
on Bruker AV-400 or Bruker AV III 600 spectrometers. Data processing
was carried out using XWIN-NMR version 3.6 (Bruker U.K. Ltd). 1H
NMR chemical shifts were internally referenced to TMS via 1,4-dioxane
in D2O (δ = 3.75), residual DMSO (δ = 2.52 ppm) or CHCl3 (δ =
7.26 ppm). 1D spectra were recorded using standard pulse sequences.
Typically, data were acquired with 16 transients into 32 k data points
over a spectral width of 14 ppm and for the kinetic experiments, 32
transient into 32 k data points over a spectral width of 30 ppm using a
relaxation delay of 2 s.
2.3. pH* measurements
pH* values (pH meter reading without correction for the effect of
deuterium on glass electrode) were measured at ambient temperature
using a minilab IQ125 pH meter equipped with a ISFET silicon chip pH
sensor and referenced in KCl gel. The electrode was calibrated with Al-
drich buffer solutions of pH 4, 7 and 10. pH* values were adjusted
with KOH or HClO4 solutions in D2O.2.4. Elemental analysis
Elemental analyses were performed by Warwick Analytical Service
using an Exeter Analytical elemental analyzer (CE440).
2.5. Electrospray ionisation mass spectrometry (ESI-MS)
Positive ion electrospray mass spectra were obtained on a Bruker
Daltonics Esquire 2000 ion trap mass spectrometer. All samples
were prepared in methanol (100%). Data were processed using Data-
Analysis version 3.3 (Bruker Daltonics).
2.6. Synthesis
2.6.1. [(Cp*)RhCl2]2
Hydrated rhodium(III) trichloride (500mg, 2.12 mmol) was reacted
with 2,4-pentamethylcyclopentadiene (302 mg, 2.22 mmol) dissolved
in dry methanol (50 mL) and heated to reﬂux (343 K) under a nitrogen
atmosphere for 48 h. The dark red precipitate was ﬁltered off and
washed with ether (3 × 20 mL) to give a dark red powder. The crude
product was then recrystallised from methanol. Yield: 410.6 mg
(62.7%). 1H NMR (400 MHz, DMSO-d6): δH 1.627 (s, 10 H).
2.6.2. [(CpxPh)RhCl2]2
[(CpxPh)RhCl2]2 was synthesised following the same procedure
described for [(Cp⁎)RhCl2]2 using hydrated Rh(III)Cl3 (500.7 mg,
1.05 mmol) and HCpxPh (532.5 mg, 2.68 mmol). The red precipitate
was recrystallised from methanol. Yield: 592.7 mg (75.47%). 1H NMR
(400 MHz, DMSO-d6): δH 7.67 (m, 4 H), 7.43 (m, 6 H), 1.71 (s, 4 H),
1.67 (m, 4 H).
2.6.3. [(CpxPhPh)RhCl2]2
[(CpxPhPh)RhCl2]2 was synthesised following the procedure
described for [(Cp⁎)RhCl2]2 using hydrated Rh(III)Cl3 (992.6 mg,
2.1 mmol) and HCpxPhPh (960.5 mg, 4.4 mmol). The red–orange precip-
itate obtained was recrystallised from methanol. Yield: 613.4 mg
(33.2%). 1H NMR (400 MHz, DMSO-d6): δH 7.75 (m, 12 H), 7.49 (t, 4 H,
J = 7.4 Hz), 7.40 (t, 2 H, J = 7.4 Hz), 1.73 (s, 24 H).
2.6.4. General synthesis of complexes 1–9
The Rh(III) dimer was placed in a round-bottom ﬂask to which dry
dichloromethanewas added. Upon addition of the corresponding ligand
(2-2.5 mol. equiv.), the reaction was stirred overnight at ambient tem-
perature, after which the solvent was removed on a rotary evaporator
to afford a crude powder. The crude product was re-dissolved in meth-
anol and ﬁltered. Excess ammonium hexaﬂuorophosphate was then
added and the solution stored in the freezer. The resulting product
was collected by ﬁltration and recrystallised from acetone or methanol.
2.6.5. [(Cp*)Rh(en)Cl]PF6 (1)
[(Cp*)RhCl2]2 (51.3 mg, 83.0 μmol), ethylenendiamine (9.88 mg,
0.16 mmol, 11 μl). Bright yellow crystals were collected. Yield:
42.3 mg (78.3%). 1H NMR (400 MHz, CDCl3): δH 5.91 (s, 2 H), 3.05 (s,
2 H), 2.88 (s, 2 H), 2.74 (s, 2 H), 1.90 (s, 15 H). Anal: Calc for
C12H23ClF6N2PRh C: 27.91, H: 4.61, N: 6.21; Found C: 28.11, H: 4.81, N:
5.95. ESI-MS: Calc for C12H23ClN2O2Rh (M)+ 333.0m/z found 333.0m/z.
2.6.6. [(CpxPh)Rh(en)Cl]PF6 (2)
[(CpxPh)RhCl2]2 (50.5 mg, 68.0 μmol), ethylenendiamine (8.99 mg,
0.15 mmol, 10 μl). Recrystallisation from methanol resulted in bright
yellow crystals. Yield: 31.7 mg (59.0%).1H NMR (400 MHz, CDCl3): δH
7.49 (m, 5 H), 5.59 (s, 2 H), 3.11 (s, 2 H), 3.02 (s, 2 H), 2.76 (s, 2 H),
2.05 (s, 6 H), 1.91 (s, 6 H). Anal: Calc for C17H25ClF6N2PRh C: 37.76, H:
4.66, N: 5.18; Found C: 37.02, H: 4.67, N: 5.26. ESI-MS: Calc for
C17H25ClN2Rh (M)+ 395.0 m/z found 395.0m/z.
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[(CpxPhPh)RhCl2]2 (51.6mg, 57.6 μmol), ethylenendiamine (7.11mg,
0.12mmol, 8 μl). Recrystallisation frommethanol resulted in bright yel-
low crystals. Yield: 47.7 mg (54.2%) 1H NMR (400 MHz, CDCl3): δH 7.69
(d, 2 H, J = 8.4 Hz), 7.60 (m, 4 H), 5.49 (t, 2 H, J = 7.5 Hz), 7.41 (t, 1 H,
J = 7.5), 5.59 (s, 2 H), 3.14 (s, 2 H), 3.03 (s, 2 H), 2.79 (s, 2 H), 2.07 (s,
6 H), 1.97 (s, 6 H). Anal: Calc for C23H29ClF6N2PRh C: 44.79, H: 4.74, N:
4.54; Found C: 43.98, H: 4.65, N: 4.54. ESI-MS: Calc for C23H29ClN2Rh
(M)+ 471.1 m/z, found 471.1 m/z.
2.6.8. [(Cp*)Rh(bpy)Cl]PF6 (4)
[(Cp*)RhCl2]2 (100.1 mg, 162 µmol), 2,2′-bipyridine (64.7 mg,
414 µmol) Recrystallization from acetone resulted in bright orange crys-
tals. Yield: 126.6mg (67.9%). 1HNMR (400MHz, Acetone-d6): δH 9.14 (d,
2H, J=5.7Hz), 8.67 (d, 2H, J=8.1Hz), 8.38 (t, 2H, J=8.0Hz),7.95 (dd,
2 H, J1 = 8.0 Hz, J2 = 5.7 Hz), 1.82 (s, 15 H). Anal: Calc for
C20H23ClF6N2PRh C: 41.8, H: 4.03, N: 4.87; Found C: 41.85, H: 3.97, N:
4.84. ESI-MS: Calc for C20H23ClN2Rh (M)+ 430.1m/z found 430.0m/z.
2.6.9. [(CpXPh)Rh(bpy)Cl]PF6 (5)
[(CpxPh)RhCl2]2 (101.3 mg, 136 µmol, 2,2′-bipyridine (56.0 mg, 359
µmol). Recrystallization from acetone resulted in bright orange crystals.
Yield: 113.5 mg (65.2%).1H NMR (400 MHz, Acetone-d6): δH 8.85 (d,
2 H,J = 5.5 Hz), 8.70 (d, 2 H, J = 8.1 Hz), 8.37 (t, 2 H, J = 8.4 Hz), 7.85
(t, 2 H, J = 6.4 Hz), 7.76 (d, 2 H, J = 6.6 Hz), 7.60 (m, 3 H), 1.92 (s,
6 H), 1.85 (s, 6 H). Anal: Calc for C25H25ClF6N2PRh + acetone C: 48.40,
H: 4.50, N: 4.03; Found C: 49.89, H: 4.22, N: 3.93. ESI-MS: Calc for
C25H25ClN2Rh (M)+ 490.1 m/z found 490.0m/z.
2.6.10. [(CpxPhPh)Rh(bpy)Cl]PF6 (6)
[(CpxPhPh)RhCl2]2 (100.8mg, 112 µmol) 2,2′-bipyridine (45.2mg, 112
µmol). Recrystallization from acetone resulted in bright orange crystals.
Yield: 87.2 mg (54.3%) 1H NMR (400 MHz, Acetone-d6): δH 8.91 (d, 2 H,
J = 8.2 Hz), 8.89 (d, 2 H, J = 8.4 Hz), 8.35 (t, 2 H, J = 8.0 Hz), 7.87 (m,
6 H), 7.79 (d, 2 H, J = 7.6 Hz), 7.54 (t, 2 H, J = 7.6 Hz), 7.45 (t, 1 H,Fig. 1. Rh(III) complexes studied in this work, for the reduction of NAD+ bJ = 7.6 Hz), 1.95 (s, 6 H), 1.90 (s, 6 H). Anal: Calc for C31H29ClF6N2PRh
C: 52.23, H: 4.10, N: 3.93; Found C: 52.73, H: 4.31, N: 3.70. ESI-MS: Calc
for C31H29ClN2Rh (M)+ 567.1 m/z, found 567.0 m/z.2.6.11. [(Cp*)Rh(phen)Cl]PF6 (7)
[(Cp*)RhCl2]2 (100.2 mg, 162 µmol), 1,10-phenanthroline
(80.78 mg, 448 µmol). Recrystallization from acetone resulted in bright
orange crystals. Yield: 138.7 mg (71.4%). 1H NMR (400 MHz, CDCl3): δH
9.43 (d, 2 H, J = 5.2 Hz), 8.71 (d, 2 H, 8.1 Hz), 8.29 (dd, 2 H, J1 = 8.2 Hz,
J2 = 5.2 Hz), 8.1 (s, 2 H), 1.89 (s, 15 H). Anal: Calc for C22H23ClF6N2PRh
C: 44.13, H: 3.87, N: 4.68; Found C: 44.13, H: 3.79, N: 4.62. ESI-MS: Calc
for C22H23ClN2Rh (M)+ 453.1 m/z found 453.0 m/z.2.6.12. [(CpXPh)Rh(phen)Cl]PF6 (8)
[(CpxPh)RhCl2]2 (124.0 mg, 167 µmol), 1,10-phenanthroline
(83.6 mg, 464 µmol). Recrystallization from acetone resulted in bright
red crystals. Yield: 130.3 mg (59.0%).1H NMR (400 MHz, CDCl3): δH
9.08 (d, 2 H, J = 5.2 Hz), 8.69 (d, 2 H, J = 8.2 Hz), 8.12 (m, 4 H), 7.78
(d, 2 H, J = 7.6 Hz), 7.61 (m, 3 H), 2.06 (s, 6 H), 1.85 (s, 6 H). Anal:
Calc for C27H25ClF6N2PRh + MeOH C: 48.54, H: 4.22, N: 4.04; Found C:
47.68, H: 4.09, N: 4.17. ESI-MS: Calc for C27H25ClN2Rh (M)+ 515.1 m/z
found 515.0 m/z.2.6.13. [(CpxPhPh)Rh(phen)Cl]PF6 (9)
[(CpxPhPh)RhCl2]2 (100.7 mg, 112 µmol), 1,10-phenanthroline
(55.8 mg, 310 µmol). Yield: 109.8 mg (66.3%) 1H NMR (400 MHz,
CDCl3): δH 9.11 (d, 2 H, J = 5.2 Hz), 8.69 (d, 2 H, J = 8.1 Hz), 8.13 (dd,
2 H, J1 = 8.1 Hz, J2 = 5.2 Hz), 8.12 (s, 2 H), 7.86 (d, 2 H, J = 8.2 Hz),
7.82 (d, 2 H, J = 8.2 Hz), 7.70 (d, 2 H J = 7.4 Hz), 7.53 (t, 2 H, J =
7.4), 7.45 (t, 1 H, J = 7.4 Hz), 2.06 (s, 6 H), 1.88 (s, 6 H). Anal: Calc for
C23H29ClF6N2PRh + MeOH C: 53.11, H: 4.33, N: 3.64; Found C: 54.37,
H: 4.34, N: 3.49. ESI-MS: Calc for C23H29ClN2Rh (M)+ 591.1 m/z, found
591.1 m/z.y transfer hydrogenation using sodium formate as a hydride source.
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[(Cp*)RhCl2]2 (49.7 mg, 80.4 μmol) and N-(2-aminoethyl)-4-
(triﬂuoromethyl)benzenesulfonamide (TfEnH) (43.5 mg, 162.2 μmol)
were dissolved in dichlormethane (25 mL) and triethylamine (45 μL,
320.5 μmol) was added. The reaction was then stirred under nitrogen
atmosphere overnight. The solution was placed in a separating funnel
and washed with brine, the organic layer separated and dried over
MgSO4 and ﬁltered. The solution was concentrated in vacuo and the
product recrystallised from methanol to afford an orange powder.
Yield: 40.3 mg (46.4%).1H NMR (400 MHz, CDCl3): δH 8.00 (d, 2 H,
J = 8.1 Hz), 7.54 (d, 2 H, J = 8.1 Hz), 3.19 (s, 2 H), 2.60 (s, 3 H), 1.71
(s, 15 H). Anal: Calc for C19H25ClF3N2O2RhS C: 42.20, H: 4.66, N: 5.18;
Found C: 41.92, H: 4.36, N: 5.01. ESI-MS: Calc. for C19H25ClF3N2O2RhS
(M-Cl)+ 505.0m/z, found 505.0 m/z.2.7. Aqueous solution chemistry
Solutions of complexes 1–10 (1.4 mM, in 20%MeOD/80% D2O)were
prepared and 1H NMR spectra at 310 K were recorded at time 0
(b10 min) and 24 h. The samples were then incubated at 310 K.
Aqueous solutions of the chlorido complexes 1–10 (1.4 mM, in 20%
MeOD/80% D2O) were treated with silver nitrate (0.95 mol. equiv.)
and stirred overnight at room temperature. 1H NMR spectra were re-
corded after ﬁltration of the samples through celite to remove the silver
chloride formed.2.8. pKa determination for aqua species
Solutions of complexes 1–4, 7 and 10 (1.4 mM, D2O) were prepared
and treated with 0.95 mol equiv. of silver nitrate. The reaction mixture
was then ﬁltered through celite to obtain the corresponding aqua ad-
ducts. Changes in the chemical shifts of themethyl protons of the Cpx li-
gand protons on the aqua adductswith thepH* (pHmeter reading) over
a range from 2 to 12 were followed by 1H NMR spectroscopy. Solutions
of KOH or HClO4 in D2O were used to adjust the pH*. 1H-NMR spectra
were recorded at 298 K on a Bruker AV III 600 spectrometer. The data
were ﬁtted to the Henderson–Hasselbalch equation using Origin 7.5.2.9. Reduction of pyruvate and NAD+
Complexes 1–3 and 10 were dissolved in D2O (1.4 mM, 4 mL) in a
glass vial. Complexes 1–9 were prepared in MeOD/D2O (3:2 v/v)
(1.4 mM, 4 mL) in a glass vial and treated with 0.95 mol. equiv. of silver
nitrate.
Aqueous solutions of sodium formate (25 mol equiv.) and substrate
(2–9 mol equiv., substrate = NAD+ or pyruvate) in D2O were also pre-
pared and incubated at 310 K. In a typical experiment, an aliquot of
200 μL of the complex, formate and substrate solutions were added to
a 5 mm NMR tube. The pH* of the solution mixture was adjusted to
7.2 ± 0.2 bringing the total volume to 0.635 mL. 1H NMR spectra were
recorded at 310 K every 162 s until the completion of the reaction.
Molar ratios of substrate and product were determined by integrat-
ing the peaks for NAD+, pyruvate, lactate and 1,4-NADH. The turnover
number (TON) for the reaction was calculated as follows:
TON ¼ Ix
Ix þ Iy
substrate½ 0
Catalyst½ 
where In is the integral of the signal at n ppm. x = 6.96 (NADH)
or 1.32 ppm (lactate). y = 9.33 (NAD+) or 2.36 ppm (pyruvate).
[substrate]0 is the concentration of NAD+ or pyruvate at the start of
the reaction.2.10. Mechanistic studies
A set of four experiments was performed to compare the character-
istics of the catalytic cycle of Rh(III) complexes 1 and 10 (1.4 mM, D2O)
with their Ru(II) analogues.
The turnover frequencies for the reduction reaction of NAD+ using
complexes 1 or 10 and formate (25 mol equiv.) were determined fol-
lowing the procedure described above. The reaction was studied using
different concentrations of NAD+ (1, 2 and 5 mol equiv. for complex
10; 5, 7.5 and 10 mol equiv. for complex 1).
A second series of experiments using different concentrations of
sodium formate (5, 10, 25, 50 and 100 mol equiv. for complex 1; 10,
25, 50, 100 and 500 mol equiv. for complex 10) and a constant
concentration of NAD+ (5 mol equiv.) was also performed.
The optimum pH range for the catalytic process was studied in a se-
ries of experiments. Each experiment was performed at a different pH*
over a range from6 to 10. The pH* of the reactionwas adjusted using so-
lutions of KOH or HClO4 in D2O.
Transfer hydrogenation reactions using 1,4-NADH (400 μL, 2.8mM) as
a hydride source (400 μL, 2.8 mM) in D2O by complexes 1 and 10 were
studied by 1H NMR for a period of 10 h. The pH* of the reaction mixture
was adjusted to 7.2 ± 0.2, and the experiments performed at 310 K.
2.11. Competition studies
Complex 1 (1.4 mM) was dissolved in CD3OD/D2O (3:2 v/v,4 mL) in a
glass vial. Aqueous solutions of sodium formate (100 mol equiv.), NAD+
(4.5mol equiv.) and pyruvate (4.5mol equiv.) in D2Owere also prepared
and incubated at 310 K. In a typical experiment, an aliquot of 200 μL of
complex, 50 μL of formate and 150 μL of pyruvate and NAD+ were
added to a 5mmNMR tube. The pH* of the solutionmixturewas adjusted
to 7.2 ± 0.2 bringing the total volume to 0.635 mL 1H NMR spectra were
recorded at 310 K every 162 s until the completion of the reaction.
2.12. Antiproliferative activity and cell viability modulation assays
The antiproliferative activities of complexes 1–10 in A2780 ovarian
cancer cells were determined. Brieﬂy, 96-well plates were used to seed
5000 cells per well. The plates were pre-incubated in drug-free media at
310 K for 48 h before addition of various concentrations of the com-
pounds. The drug exposure periodwas 24 h, after which, the supernatant
was removed by suction and each well washed with PBS. A further 48 h
was allowed for the cells to recover in drug-free medium at 310 K. The
sulforhodamine B (SRB) colorimetric assaywas used to determine cell vi-
ability [21]. IC50 values, as the concentrationwhich causes 50% growth in-
hibition, were determined as duplicates of triplicates in two independent
sets of experiments and their standard deviations were calculated.
The data were analysed using Origin 8.5. IC50 values were obtained
from plots of the percentage survival of cells versus the logarithm of
the concentration expressed inmillimolar units andﬁtted to a sigmoidal
curve. IC50 values for cisplatin were determined in each well-plate as a
validation.
Cell viability modulation assays were carried out in A2780 ovarian
cancer cells. These experiments were performed as described above for
IC50 determinations with the following experimental modiﬁcations. A
ﬁxed concentration of complexes was used, 150 μM. Co-administration
of the complex with three different concentrations of sodium formate
(0.5, 1 and 2 mM) was studied. Both solutions (complex and sodium for-
mate) were added to each well independently, but within 5 min of each
other. Cell viability percentages were determined as duplicates of tripli-
cates in two independent sets of experiments and their standard devia-
tions were calculated.
Stock solutions of the Rh(III) complexes were freshly prepared for
every experiment in 5% DMSO and a mixture 0.9% saline : medium
(1:1 v/v). The stock solution was further diluted using RPMI-1640 to
achieve working concentrations. The ﬁnal concentration of DMSO was
Fig. 2. Dependence of 1H NMR chemical shifts of complexes 1–4 and 6 on pH*. The lines
represent computer ﬁts to the Henderson–Hasselbalch equation with the pKa values in
Table 1.
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ICP-MS.
3. Results
Rh(III) complexes 1–9were synthesised (Fig. 1) using a similar pro-
cedure. Typically, the ligand (2–2.5mol equiv), was added to a dichloro-
methane solution of the rhodium dimer, [(Cpx)RhCl2]2 and the reaction
mixture stirred at ambient temperature. The details for individual
reactions are described in the experimental section. Complex 10 was
synthesised by reacting the dimer with the TfEnH ligand in dichloro-
methane, and in the presence of triethylamine (4mol equiv) at ambient
temperature overnight.
The complexes were characterised by elemental analysis, NMR
spectroscopy andmass spectrometry. The x-ray crystal structures of com-
plexes 3–6, 8 and 9were determined and will be reported elsewhere.
3.1. Aqueous solution chemistry
Aquation of complexes 1–10 (1.4 mM in 20% MeOD/ 80% D2O) at
310 K was followed by 1H NMR over a period of 24 h. For complexes
1–3 and 10, only one set of peaks (aqua adducts) was observed. For
complex 4–9, two sets of peaks were observed and assigned as the
chlorido and the aqua species. Peaks for aqua species were assigned
by comparison of the 1H spectra of 1–10 in D2O and the products of re-
actions between 1–10with silver nitrate. After 24 h incubation (310 K),
no apparent changes were observed by 1H NMR. Compounds 6 and 9
gave rise to precipitates after 24 h and 1H NMR spectra could not be re-
corded. The extent of hydrolysis is shown in Table 1.
Changes in the 1H NMR chemical shifts of the methyl groups of
cyclopentadienyl protons from the aqua adducts of complexes 1–4, 7
and 10 were followed over the pH* range from 2 to 12. The data were
ﬁtted to the Henderson–Hasselbalch equation. The pKa* values for com-
plexes 1–4, 7 and 10 are shown in Table 1 (Fig. 2).
3.2. Transfer hydrogenation reactions with NAD+
Catalytic conversion of NAD+ to NADH using complexes 1–10 and
sodium formate (hydride source) was followed by 1H NMR spectrosco-
py. In a typical experiment, 200 μL of complex (1.4 mM, D2O or MeOD/
D2O 3:2 v/v), sodium formate (35 mM, D2O) and NAD+ (2.8–12.6 mM,
D2O) were mixed in a 5 mm NMR tube, ﬁnal ratio 1:25:2–9, complex :
sodium formate : NAD+. The pH* of the reaction mixture was adjusted
to 7.2 ± 0.2. 1H NMR spectra at 310 K were recorded every 162 s until
completion of the reaction. The turnover frequencies (TOF) for the
reactions were determined as described in the experimental section
(Table 2).
The turnover frequencies for complexes 1–3 in D2O, increased
in the order Cp *bCpxPhbCpxPhPh (Table 2). The most active complexTable 1
Hydrolysis of complexes 1–10 and pKa* values for their aqua adducts.
Complex
Hydrolysis1
(%) pKa⁎2
1 100 9.35 ± 0.06
2 100 9.48 ± 0.06
3 100 9.35 ± 0.02
4 56 8.84 ± 0.08
5 38
6 49
7 59 8.86 ± 0.06
8 39
9 48
10 100 N10
1 In 20% MeOD/80% D2O (v/v) at 310 K; the reactions reached equilibrium by the time
the ﬁrst spectrum was recorded b10 min.
2 In D2O at 298 K;− not determined.was [(CpxPhPh)Rh(en)Cl]+ (3), with a TOF of 24.19 h−1. The reaction
was regioselective giving 1,4-NADH exclusively. On changing the
ethylendiamine (en) chelating ligand (complex 1) to N-(2-
aminoethyl)-4-(triﬂuoromethyl)benzenesulfonamide (TfEn) (complex
10), the catalytic activity decreased (Table 2). Furthermore, a decrease
in the regioselectivity of the reaction was also observed with 7.5% of
1,6-NADH being produced.
Complex 1was less active than complex 2 in the reduction of NAD+
in 20%MeOD/80%D2O, following the same trend as observed for the re-
action in D2O. However, the catalytic activity of complexes 1 and 2 in
20% MeOD was 2× times higher than that in D2O.
Complexes 4–9were also studied for the reduction of NAD+ in 20%
MeOD/80% D2O. Complexes containing Cp* (4 and 7) were more active
than those containing CpxPh (5 and 7), which, in turn, were more active
than CpxPhPh complexes (6 and 8), (Table 2). The reactions of complexes
4–9were largely regioselective, giving only 1 to 10% of 1,6-NADH.Table 2
Turnover frequencies (TOF) for the reduction of NAD+ by complexes 1–6 and 10–13. The
reactionswere carried out either in D2O or 20%MeOD/80% D2O (v/v) using 6–9mol equiv.
NAD+ and 25mol equiv. formate. pH* was adjusted to 7.2± 0.2 and the spectra recorded
at 310 K.
Complex CpX N,N′
TOF (h−1)
D2O
TOF (h−1)
MeOD/D2O
1 Cp* en 7.50 ± 0.06 17.98 ± 0.01
2 CpxPh en 19.65 ± 0.01 35.5 ± 0.9
3 CpxPhPh en 24 ± 1 –
4 Cp* bpy – 37 ± 2
5 CpxPh bpy – 27.7 ± 0.7
6 CpxPhPh phen – 16.4 ± 0.2
7 Cp* phen – 28.0 ± 0.7
8 CpxPh phen – 18.6 ± 0.5
9 CpxPhPh phen – 8.2 ± 0.3
10 Cp* TfEn 4.12 ± 0.01 –
Fig. 3. (a) Plot of the TOF versus formate concentration (5, 10, 25, 50 or 100 mol equiv), for
the reduction of NAD+ catalysed by complex [(Cp*)Rh(en)Cl]+ (1) at pH* 7.2 and 310 K. A
typicalMichaelis–Menten behaviour is observed. (b) Plot of the reciprocal of the TOF against
formate concentration, for catalysis by complex 1. ForMichaelis-type kinetics, TOF−1=(KM/
TOFmax)(1/[S])+(1/TOFmax).Michaelis constant (KM=54.16mM)and themaximumturn-
over frequency (TOFmax = 41.49 h−1) were determined. (c) Plot of the TOF against the for-
mate concentration (5, 10, 25, 50 or 100 mol equiv), TOF = TOFmax [S]/(KM + [S]) by
complex [(Cp*)Rh(TfEn)Cl]+ (10) at pH* 7.2 and temperature 310 K. (d) Plot of the recipro-
cal of the TOF against formate concentration, for catalysis by complex 10. ForMichaelis-type
kinetics, TOF−1=(KM/TOFmax)(1/[S])+ (1/TOFmax).Michaelis constant (KM=108.37mM)
and the maximum turnover frequency (TOFmax = 37.24 h−1) were determined.
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Transfer hydrogenation reactions using complex 1, sodium formate
and varying concentrations of NAD+ were studied (ratio of 1:25:X,
X = 5, 7.5 and 10 mol equiv. of NAD+). The turnover frequency
(7.5 h−1) remained the same with increasing concentrations of NAD+.
For complex 10, the TOF (4.12 h−1) was unaffected by the concentra-
tion of NAD+ (X = 1, 2 or 5 mol equiv.).
A second series of experiments on the reduction of NAD+, varying
the concentration of sodium formate, was performed (complex 1, sodi-
um formate and NAD+ in the ratio 1:X:5, X = 5, 10, 25, 50 or 100 mol
equiv.). A notable increase in the catalytic activitywas observedwith in-
crease of the hydride source (sodium formate), (Fig. 3). From the plot of
TOF vs formate concentration, typical Michaelis–Menten behaviour is
observed. From the reciprocal of the TOF vs formate concentration, a
maximum turnover frequency (TOFmax) of 41.49 h−1 and a Michaelis
constant (KM) of 54.16 mMwere calculated.Fig. 4. Dependence of turnover frequency on pH* for the reduction of NAD+ by complex 1
using formate as a hydride source (mol. ratio 5:1:25, respectively, 310 K in D2O). Maxi-
mum turnover frequency achieved at pH* 7.3 ± 0.1.The TOFmax (37.24 h−1) and KM (108.37 mM) for complex
[(Cp*)Rh(TfEn)Cl] (10) were also determined by performing a series
of experiments with different concentrations of sodium formate (10,
25, 50, 100 or 500 mol equiv.), Fig. 3.
3.2.2. pH dependence
The pH* dependence of the catalytic reaction (frompH* 4 to 10) was
also investigated via a series of experiments using complex 1, sodium
formate and NAD+ (ratio 1:25:6, respectively) in D2O. A dependence
on pH* was observed. The highest TOF (7.5 h−1) was achieved at pH*
7.3 ± 0.1, however the turnover frequencies between pH* 6 and 8 are
similar. A decrease in the catalytic activity was observed when the
pH* is higher than 9 (Fig. 4).
3.2.3. Transfer hydrogenation reactions using NADH as a hydride donor
NADH has previously been shown to be able to act as a hydride
donor [14]. As a consequence, experiments in which complexes 1–3
and 10were reacted with NADHwere performed, however, no hydride
transfer from NADH was observed over a period of 10 h.
3.3. Transfer hydrogenation reactions with pyruvate
Lactate formation via hydride transfer from formate to pyruvate
catalysed by complexes 1–9was followed by 1HNMR. In a typical exper-
iment, 200 μL of complex (1.4 mM, D2O or MeOD/D2O 3:2 v/v), formate
(35 mM, D2O) and pyruvate (7 mM, D2O) were mixed in a 5 mm NMR
tube, ﬁnal ratio 1:25:5, complex : formate : pyruvate. 1H NMR spectra
at 310 K were recorded every 162 s until completion of the reaction.
Molar ratios of pyruvate and lactate were determined by integrating
the signals of pyruvate (3 H, singlet, 2.36 ppm) and of lactate (3 H,
singlet, 1.32 ppm), Fig. 5. The activity of the complexes towards reduc-
tion of pyruvate to lactate is dependent on the nature of both the CpX
ring and the N,N′ chelating ligand. Extended CpXPhPh rings result in anFig. 5. 1H NMR spectra for the reaction of complex 1, formate and pyruvate inmolar ratios
of 1:25:6, respectively, in 20% MeOD/80% D2O (v/v) at 310 K and pH* 7.2 ± 0.2.
Fig. 6. Dependence of the turnover frequencies for the reduction of pyruvate to lactate on
theCpx ring substituent (Ph) and chelated ligand (bpy, phenor en) for complexes 1, 2, 4, 5,
7 and 8. The reactions were carried out in 20% MeOD/80% D2O (v/v) using 6–9 mol equiv.
pyruvate and 25mol equiv. formate. The pH*was adjusted to 7.2± 0.2 and the NMR spec-
tra recorded at 310 K.
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was a decrease in the TOF when the N,N′-chelated ligand is 2,2′-
bipyridine (bpy) or phenanthroline (phen) (Fig. 6).
3.4. Competition for the reduction between NAD+ and pyruvate
Transfer hydrogenation reactions with complex [(Cp*)Rh(bpy)Cl]+
(4), sodium formate, and both NAD+ and pyruvate as hydride acceptorsFig. 7. 1H NMR spectra for the reaction of complex 4, formate and NAD+ and pyruvate in
molar ratios of 1:25:4.5:4.5, respectively, in 20% MeOD/80% D2O (v/v) at 310 K and pH*
7.2 ± 0.2. 1 TOF measured in D2O.were performed. For these experiments, 4.5mol equiv. of NAD+ and py-
ruvate were reduced using 25 mol equiv. of formate.
The reduction of both NAD+ and pyruvate by complex 4 was
observed, but the rate of reduction was slower for both substrates
(Fig. 7). In addition, pyruvate was reduced only when the reduction of
NAD+ was almost complete.3.5. Cancer cell growth inhibition
The IC50 values for Rh(III) complexes 1–10 in A2780 human ovar-
ian cancer cells were determined (Table 3). Complexes 1–3 and 10
were inactive up to the maximum concentration tested (100 μM).
Complexes 4–9 were moderately active with IC50 values between
14 and 65 μM.
The percentage cell survival of A2780 cells after incubation with
complexes 1–10 and varying concentrations of sodium formate (0, 0.5,
1, 2 mM) was determined (Fig. 8). A signiﬁcant increase of the antipro-
liferative activity of the Rh(III) complexes upon addition of formate is
evident. The largest increase was observed for complex [(Cp-
xPhPh)Rh(en)Cl]+ (3), with a decrease in cell survival of up to 50%.4. Discussion
Ruthenium(II), rhodium (III) and Iridium (III) half sandwich com-
plexes have previously been reported to catalyse the reduction of
NAD+ via transfer hydrogenation using sodium formate as a hydride
source [22-24]. In the previous reports, Rh(III) complexes generally
displayed higher turnover frequencies (TOF) than Ir(III), while Ru(II)
complexes have the lowest catalytic activity [15,16,25–27]. However,
the reported catalytic reactions were usually carried out under non-
physiological conditions: high temperatures, very high concentrations
of formate, pH ≠ 7.4 or with high concentrations of non-aqueous sol-
vents [15,16,25–27].
The complexes selected for the present work have all already been
studied for the reduction of NAD+ under non-physiological conditions:
[(Cp*)Rh(bpy)Cl]+ (4), developed by Steckhan and Fish [27,28],
[(Cp*)Rh(phen)Cl]+ (7), published by Süss-Fink [26], [(Cp*)Rh(en)Cl]+
(1), rhodiumanalogue of [(p-cym)Ru(en)Cl]+ studied in our group [16],
and [(Cp*)Rh(TfEn)Cl]+ (10).
Noyori-type catalysts such as [(Cp*)Rh(TfEn)Cl] (10) are someof the
more successful catalysts for transfer hydrogenation reactions [3]. Re-
duction of NAD+ using Noyori-type catalysts has been recently studied
successfully by several groups [15,29,30].
In our previous work, we observed that the nature of arene and
Cp rings can have a signiﬁcant effect on the catalytic properties of
half-sandwich metal complexes. For example, iridium complexes
containing Cpx with extended aromatic substituents had improved
catalytic activity for the regeneration of NAD+ [14]. With this in
mind, complexes containing CpxPh and CpxPhPh rings were studied
in the present work.Table 3
IC50 values for complexes 1–10 in A2780 human ovarian cancer cells.
Complex CpX N,N′ IC50(μM)
1 Cp* en N100
2 CpXPh en N100
3 CpXPhPh en 100
4 Cp* bpy 64 ± 1
5 CpXPh bpy -
6 CpXPhPh bpy 36.07 ± 0.07
7 Cp* phen 17.8 ± 0.6
8 CpXPh phen 57 ± 1
9 CpXPhPh phen 14.68 ± 0.05
10 Cp* TfEn N100
Fig. 8. (a) Survival of A2780 humanovarian cancer cells when treatedwith complexes 1–4 and 6–10 (concentration=1/3 IC50 for 4–9, 150 μM for 1–3 and 10) and varying concentrations
of sodium formate (key to shading of bars: 0 (white), 0.5, 1 or 2 (black) mM). *P b 0.05, **P b 0.01. Cell survival was normalised to the % survival of cells treated onlywith Rh(III) complex.
(b) Table showing the % decrease in cell survival and the TOF for the reduction of NAD+ (in 20% MeOD/80% D2O, pH 7.2 ± 0.2, 310 K) for complexes 1–4 and 6–10.
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Previous studies with related compounds have shown that the 16e–
species or the aqua adducts of the complexes are the active catalysts in
transfer hydrogenation reactions [2,31]. However, in aqueousmedia the
presence of water and pH has been shown to play a critical role [2,31].
Aquation of the complexes 1–10 in 20% MeOD / 80% D2O (1.4 mM)
was conﬁrmed by comparing the 1H NMR spectra of D2O solutions of
the complexes and solutions obtained after removal of the chloride li-
gand by reaction with AgNO3 to precipitate AgCl. Complexes 1–10 hy-
drolysed rapidly at 310 K, reaching equilibrium by the time the ﬁrst
1H NMR spectrumwas recorded (b10 min). Consequently the turnover
frequency for transfer hydrogenation is not affected by the use of the
chlorido complex instead of the aqua adduct.
Complete conversion of the chlorido complexes 1–3 and 10 to their
aqua adducts was observed. However, complexes 4–9 reached equilib-
rium with 30–60% formation of the aqua species (Table 1). This lower
conversion would not be expected to affect the catalytic activity since
the hydrolysis is fast, and the formation of hydrido species will shift
the equilibria towards aqua adduct formation.
pH* titrations to determine the pKa of the aqua adducts of complexes
1–4, 7 and 10 were carried out so that the nature of the complexes at
pH 7.2 (aqua or hydroxido complexes) could be determined. Theformation of hydroxido adduct would be expected to hamper the cata-
lytic reaction since hydroxido ligands bind more tightly than the aqua
ligands. The pKa* values of the aqua adducts determined byNMR pH* ti-
trations, are all N8.5 (Table 1). These complexes will therefore exist
largely as the aqua complexes at pH values close to 7.4.
4.2. Transfer hydrogenation reactions with NAD+
4.2.1. Comparison of Ru(II) and Rh(III)
First, we compared the catalytic activity for the reduction of NAD+
by [(Cp*)Rh(en)Cl]+ (1) and [(Cp*)Rh(TfEn)Cl] (13) with the arene-
Ru(II) analogues we studied previously [(hmb)Ru(en)Cl]+, [(p-
cym)Ru(TfEn)Cl] and [(bn)Ru(TfEn)Cl], (Table 4) [15,16].
The catalytic activity of the Rh(III) complexes was expected to
be higher than that of their Ru(II) analogues based on the literature.
[15,16,25–27] Complex 1 was up to 8.5× more active than
[(hmb)Ru(en)Cl]+, (Table 4). However, complex 10 had TOF values in
the same range as those of the Ru analogues [(η6-arene)Ru(TfEn)Cl]
(TOFp-cym = 3.1 h−1, TOFbn = 6.6 h−1) [15].
The TOF of complex 10was 2× lower than complex 1 (Table 4). This
decrease in catalytic activity could be due to steric hindrance generated
by the sulfonamide group. Despite the fact that half-sandwich com-
plexes containing N-(2-aminoethyl)-sulfonamides are known to
Table 4
Comparison of the catalytic cycles of ruthenium and rhodium complexes.
[(p-cym)Ru(TsEn)Cl]
[(Cp*)Rh(TfEn)Cl]
(10)
[(hmb)Ru(en)Cl]+
[(Cp*)Rh(en)Cl]
(1)
Hydrolysis Very fasta Very fast Moderateb Very fast
% aqua adduct (24 h) 100a 100 32b 100
pKa 9.71a N10 ca. 8c 9.31
TOF (h−1) 1.58a 4.12 ± 0.01 0.85d 7.50 ± 0.06
[NAD+] dependence Noa No Nod No
TOFmax (h−1) 6.4a 37.2 1.46d 41.5
KM (mM) 27.8a 108.4 58d 41.5
Optimum pH* 7.2 ± 1a NDe ND 7.3 ± 0.01
Reaction with 1,4 NADH Noe No ND No
a ref. [12], b ref. [55], c ref. [56], d ref. [16], e ND = not determined.
330 J.J. Soldevila-Barreda et al. / Journal of Inorganic Biochemistry 153 (2015) 322–333display very high catalytic activity for hydride transfer reactions [32,33]
[3,34,35], our results are perhaps not surprising, since low catalytic ac-
tivities have been previously reported with Noyori-type catalysts for
the reduction of NAD+ compared with other Rh(III) catalysts [30].
Next a series of ethylenediamine-Rh(III) complexes containing ex-
tended Cpx ligands was studied. A trend was observed in which the
presence of amore electron-withdrawing Cpx ring gives higher catalytic
activity (Table 4). Accordingly, the complex [(CpxPhPh)Rh(en)Cl]+
shows the highest activity followed by [(CpxPh)Rh(en)Cl]+ and, in
turn, both are more active than [(Cp*)Rh(en)Cl]+. With 3, an improve-
ment in the TOF of 24× was achieved, compared with the ruthenium
analogue [(hmb)Ru(en)Cl]+. This increase in activity can be attributed
to the effect of a less electron-rich Cp ring. Themore acidic metal centre
may facilitate the coordination of negatively-charged formate, which
can then undergo β-elimination to generate Rh-H and CO2.
In order to compare the reactivity of Cp-Rh(III) with their arene-
Ru(II) analogues, a set of experiments was performed using com-
plexes 1 and 10: dependence of the reaction rate on the NAD+ and
formate concentrations, reaction with NADH, and optimum pH* of
the reaction.
For reactions of [(Cp*)Rh(en)Cl]+ (1) and [(Cp*)Rh(TfEn)Cl] (10)
and varying concentrations of NAD+, no signiﬁcant alterations in the re-
action rate were observed (TOF = 7.5 and 4.1 h−1, respectively). The
unchanged turnover frequency implies that the reaction rate does not
depend on the NAD+ concentration. However, when the experiments
were performed with increasing concentrations of the hydride source
(sodium formate), the reaction rate increased, suggesting that formate
is involved in the rate-determining step (Fig. 3). This behaviour is sim-
ilar to that of [(Cp*)Rh(bpy)Cl]+ previously observed by Fish et al.
[36], with the immobilised tethered Cp*Rh complex (Rh(III)-TsDPEN)
where TsDPEN is (N-[(R,2R)-2-amino-1,2-diphenylethyl]-4-toluene
sulfonamide) studied by Hollmann et al. [30] and with [[(η6-
arene)Ru(en)Cl]+ and [[(η6-arene)Ru(TfEn)Cl] studied in our laborato-
ry [15,16]. Plotting the turnover frequency against formate concentra-
tion shows a typical Michaelis–Menten behaviour. The maximum
turnover frequency calculated from the double reciprocal of TON vs
formate concentration for complex 1 is TOFmax = 41.49 h−1, ca. 28×
higher than that of [(hmb)Ru(en)Cl]+ (TOFmax = 1.46 h−1) [16].
The TOFmax for complex 10 was 37.2 h−1, only ca. 5× higher than
that of [(p-cym)Ru(TsEn)Cl] (TOFmax = 6.9 h−1) [15]. At high concen-
trations of hydride (Sodium formate), the complexes containing TfEn
ligands are 5× timesmore active than their ruthenium analogues. How-
ever, complex [(Cp*)Rh(TsEn)Cl] (10) is still less active than the
ethylenediamine complex [(Cp*)Rh(en)Cl]+ (1).
The Michaelis constant for complex 10 (KM= 108.4 mM) indicates a
weaker afﬁnity for formate compared to complexes [(Cp*)Rh(en)Cl]+
(KM = 41.5 mM), [(hmb)Ru(en)Cl]+ (KM = 58 mM), [16] and [(p-
cym)Ru(TsEn)Cl] (42.1 mM) [15]. Comparedwith [(Cp*)Rh(bpy)H2O]2+
(KM 140 mM) [36], complex 10 shows stronger afﬁnity for formate. This
implies that the low catalytic activity when using 25 mol equiv. offormate is due to reduced afﬁnity for formate, but the catalytic activity in-
creases markedly in formate-saturated solutions.
Some iridium and ruthenium complexes such as ([Cp*Ir(phen)Cl]+,
([Cp*Ir(phenylpyridine)Cl] and[(p-cym)Ru(bipyrimidine)Cl]) have
been shown to oxidise NADH through transfer hydrogenation [13,14,
17,37]. In such processes, the NADH acts as a natural hydride donor,
and themetal catalyses hydride transfer fromNADH to other substrates
such as quinones, pyruvate or oxygen [13,14,37]. In this study, we
investigated the possibility of oxidising NADH using the rhodium(III)
complexes 1 and 10. No oxidation of NADH occurred after 12 h at
310K andpH7.2±0.2. In contrast to the above-mentioned compounds,
the lack of reactivity with NADH is similar to the ruthenium complex
[(p-cym)Ru(TfEn)Cl]. These experiments emphasise the critical
inﬂuence of the ligands in half-sandwich complexes on the reactivity
of the complex.
The last experiment performed was to determine the optimum pH*
for the reduction of NAD+. In line with our aim of applying the catalytic
reduction of NAD+ in biological systems, we worked at pH 7.2.
However, it is interesting to note the effect of pH on the reaction rate.
Surprisingly, the maximum activity for complex 1 was observed at
pH* 7.3 (Fig. 3) which is close to physiological pH. Furthermore, slight
variations were observed over the pH range 5 to 9. At pH* N 9, the con-
centration of OH− inhibits the reaction due to the formation of themore
inert Rh(III) hydroxido adduct. This effect of pH was also observed for
the ruthenium systems [2,15].4.2.2. Reduction of NAD+
In order to select the best catalyst candidate to work with, 3 well-
known half-sandwich Rh(III) compounds were studied for their
catalytic activity towards the reduction of NAD+.We also studied the ef-
fect of extended phenylation of CpX rings on their TOF. These reactions
were performed in 20% MeOD and 80% D2O to aid solubility.
As we observed previously, there is an increase on the TOF for
ethylendiamine-containing-complexes when using extended rings.
Interestingly, there is a 2-fold increase in the TOF due to the effect
of 20%MeOD. This effect was observed previously for the ruthenium(II)
complexes [(arene)Ru(TfEn)Cl]] [15].
The TOF of complexes 4–9 for the reduction of NAD+ decreases
when using CpxPh or CpxPhPh as ligands (Table 2). Those results are sur-
prising, since the trend is opposite to that for complexes 1–3. These re-
sults may be attributable to steric factors due to the extended Cp ring
and the size of the chelating ligand (bipyridine and phenanthroline
compared to ethylenediamine).
The catalytic activity for the reduction of NAD+ is also dependent on
the N,N′ chelating ligand. For complexes containing Cp*, the turnover
frequencies increase in the order en b phen b bpy, whereas for com-
plexes containing CpXPh or CpXPhPh, the TOFs increase in the order
phen b bpy b en (Table 2). Higher activity (TOF=37.4±2h−1)was ob-
tained with [Cp*Rh(bpy)Cl]+ (4). However, the catalytic activity for the
Fig. 9. Anaerobic glycolysis and role of pyruvate in cancer cells under normal conditions
(left) and possible effects due to the presence of Rh(III) complexes co-administered
with sodium formate.
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in the same range as that obtained with complex [Cp*Rh(bpy)Cl]+ (4).
4.3. Reactions with pyruvate
We initially studied the reduction of NAD+, but it is well known that
this type of catalyst can also be used for the reduction of other
molecules. Previously, the possibility of reducing biomolecules such as
pyruvate was reported, using [(Cp*)Ir(phen)Cl]+ as a catalyst [14].
Therefore, we studied the catalytic reduction of pyruvate using
complexes 1–9.
Complexes 1 and 2 reduce pyruvate in the presence of sodium
formate, and complete conversion to lactate was achieved. The com-
plex containing the Cp* ring was less active than that containing the
extended cyclopentadienyl ring (Fig. 6). Similar to the reduction of
NAD+, when using bipyridine (4–6) and phenanthroline (7–9) as
chelating ligands, the catalytic activity decreases with extended Cp
rings. Interestingly, the catalytic activity of compounds 6 and 9 was
extremely low, and after 8 h less than 30% conversion was achieved.
The complexes containing CpXPhPh were not able to reduce pyruvate
effectively before decomposition, and the reactions cannot be con-
sidered as catalytic (Fig. 6).
The low catalytic activity of complexes 1–9 for the reduction of
pyruvate was expected since both, pyruvate and formate, contain
negatively-charged carboxylate groups which can compete with
hydride for binding to Rh(III).
4.4. Competition for the reduction of NAD+ and pyruvate
Competition experiments were performed using complex
[(Cp*)Rh(bpy)Cl]+ (4). For these experiments, 4.5 mol equiv. of NAD+
and pyruvate were reduced using 25 mol equiv. of formate. The exper-
iment showed a clear preference of complex 4 for the reduction of
NAD+. NAD+ was reduced completely but at a slight lower rate than
when the reaction was performed without pyruvate (Fig. 7), attribut-
able to competitive binding of formate and pyruvate.
Pyruvate was reduced only after the levels of NAD+ became very
low. The reduction of pyruvate in the presence of NAD+was extremely
slow compared with the reduction of pyruvate on its own, with 50%
reduction of pyruvate to lactate after 2 h 15 min.
4.5. Cancer cell growth inhibition
The antiproliferative activity of complexes 1–10 in A2780 human
ovarian cancer cells was studied (Table 3). IC50 values for complexes
1–3 and 10 were higher than 100 μM (inactive), while complexes 4–9
showed moderate activity, with IC50 values between 14 and 65 μM.
Higher activities were obtained with the phenanthroline series (IC50
(7) = 17.8 ± 0.6 μM, (9) = 14.68 ± 0.08 μM). Interestingly, in all
cases lower IC50 values were obtained when using the CpxPhPh capping
ligand, perhaps due to an increase in hydrophobicity and increased
accumulation of the metal complex in cells [38,39], or due to the
intercalation of the extended aromatic unit between nucleobases of
DNA [32,33].
Cell survival with complexes 1–10 upon addition of formate at con-
centrations of 0.5, 1 and 2 mMwas also determined (Fig. 8). The com-
plexes show enhanced activity in combination with formate. Formate
alone had no effect on cell viability. It seems reasonable to propose
that co-administration of the complexes with formate gives rise to cat-
alytic transfer hydrogenation reactions in the A2780 human ovarian
cancer cells, although perhaps with few turnovers in view of the variety
of nucleophiles in the cell which might terminate the reactions.
In our previous work we have shown that transfer hydrogenation
catalysts such as [(bip)Ru(en)Cl]+ or [(p-cym)Ru(TfEn)Cl] together
with formate can reduce the levels of nicotinamide adenine dinucleo-
tide (NAD+) in cells [12]. NAD+ is an important co-enzyme involvedin maintaining the redox balance, the Kerb's cycle and other metabolic
pathways such as synthesis of ADP-ribose, ADP-ribose polymers and cy-
clic ADP-ribose which are crucial for genome stability, DNA repair, and
maintenance of calcium homeostasis [40–45]. Changes in the cellular
redox status play an important role in cell death. In particular, cancer
cells, might be more sensitive to redox variations, since they are under
constant oxidative stress due to high production of reactive oxygen
species (ROS) [40–45].
Despite the higher catalytic activity towards the reduction of NAD+
of the Rh(III) complexes 1–10 compared with the Ru(II) complexes
studied previously [15,16], the enhancement in antiproliferative activity
of the Rh(III) complexes is not as high as for their Ru(II) analogues [12].
The increase in catalytic activity for the reduction of NAD+does not cor-
relate with an increase in antiproliferative activity when the drugs are
co-administered with sodium formate (Fig. 8b). The inconsistency be-
tween the catalytic activity and effects on cells might be due to various
factors. The poisoning of the catalyst [46], for example. Ward et al. have
studied the possibility of synthesizing Ir(III) Noyori-type catalysts capa-
ble of reducing NAD+, quinones and ketones [29,47]. In order to reduce
poisoning due to sulphur-containingmolecules, such as glutathione, the
compounds were conjugated to biotin-streptavidine [47]. The artiﬁcial
metalloenzyme was able to carry out transfer hydrogenation reactions
and reduce, to a certain extent, the effect of poisoning due to glutathione
[47].
The anticancer activity of the compounds may be due in part not
only to the reduction of NAD+but also other biomolecules. For example,
in thisworkwe have demonstrated that complexes 1–5 and 7–8 can re-
duce pyruvate, while compounds 6 and 9 cannot. Pyruvate is an essen-
tial component of cellular energy pathways (Krebs' cycle) and of special
importance in cancer cells. It has been previously observed that cancer
cells consume high levels of glucose and release lactate and carbon
dioxide (Warburg effect) [48,49]. This behaviour is linked to the
malfunctioning of mitochondria. Cancer cells have a high rate of con-
sumption of glucose (glycolysis) due to the need to generate nutrients
such as nucleotides and amino acids. However, a high rate of glycolysis,
requires high levels of NAD+. Cancer cells regenerate NAD+ at a very
fast rate by reducing pyruvate to lactate (Fig. 9) [48,49].
In the presence of the Rh(III) catalysts 1–5 and 7–8, the pool of
pyruvate in cells may be reduced due to conversion to lactate. As a con-
sequence, the regeneration of NAD+ and the anaerobic glycolysis in
cancer cellswill be disrupted. The reduction of pyruvate, in combination
with the reduction of NAD+ will affect not only the redox regulatory
332 J.J. Soldevila-Barreda et al. / Journal of Inorganic Biochemistry 153 (2015) 322–333system of the cell, but also the generation of ATP (energy) and forma-
tion of various nutrients necessary for cell growth and reproduction.
5. Conclusions
During the last decade, there has been increasing interest in
developing metal-based catalysts which are effective in cells. Such
technology might be useful in areas such as protein labelling, imaging,
and for the treatment of diseases. For example, Chen and
Meggers have shown that metal compounds such as Pd(dba)2 or
[CpRu(QA)(η3-allyl)]PF6 (QA = 2-quinolinecarboxylate) can be
used to remove protector groups from N-protected anticancer drugs
[50,51]. Cowan et al. have shown that Cu(II)/Ni(II)-ATCUN compounds
can decompose RNA in hepatitis or HIV [52,53]. Also organo-
ruthenium compounds can oxidise glutathione catalytically [54].
In the current work, we have studied the possibility that the Rh(III)
complexes [(Cpx)Rh(N,N′)Cl] may be more active catalysts than their
Ru(II) arene analogues. Four series of compounds which can reduce
NAD+ toNADHusing formate as a hydride source, have been investigat-
ed under biologically-relevant conditions (aqueous solution, pH = 7.2,
310 K). The catalytic activity decreased in the order of N,N-chelated
ligand bpy N phen N en with Cp* as the η5-donor. However, while the
ethylenediamine-containing compounds (1–3) became more active
with extension to the CpX ring,we observed a decrease in catalytic activ-
ity for N,N-chelated phenanthroline- (7–9) and bipyridine– (4–6) com-
pounds, perhaps due to an increase in steric hindrance. The complex
[Cp*Rh(bpy)Cl]+ (4) showed the highest catalytic activity towards the
reduction of NAD+, with a TOF of 37.4 ± 2 h−1.
The catalytic activity of complexes [CpxRh(en)Cl]+ (1–3) (7.50,
19.65 and 24.19 h−1, respectively) is up to two orders of magnitude
higher than for their Ru(II) analogues (TOF [(hmb)Ru(en)Cl] + =
0.85 h−1). Interestingly, Noyori type Rh(III) compounds such as 10
with a turnover frequency of 4.12 h−1, display nomarked improvement
compared to the Ru(II) arene analogues (c.f. 6.62 h−1 for
[(bn)Ru(TfEn)Cl]).
Mechanistic studies on these Rh(III) complexes were carried out in
order to investigate the catalytic cycle. Fast hydrolysis of the chlorido
complexes 1–10 was observed by 1H NMR (b10 min at 310 K). Com-
pounds 1–3 and 10 gave quantitative conversion to aqua adducts,
while complexes 4–9 (at millimolar concentrations) reached equilibri-
um with a 30–60% of the aqua species present. The pKa* values deter-
mined for the aqua adducts of ca. 8–10 indicate that the Rh(III)
complexes are likely to be present in their aqua forms around pH 7 rath-
er than forming less reactive hydroxido species. Complexes 1 and 10
showed a dependence of the reaction rate on formate concentration,
but not on NAD+ concentration. No reaction between complexes 1–4
and 1,4-NADH was detected after 10 h. Optimum pH* for the reaction
with complex 1 was 7.3 ± 0.1, close to physiological pH. These results
indicate that these Rh(III) Cpx compounds exhibit similar behaviour to
their Ru(II) arene analogues.
Themaximum turnover frequencies of Rh(III) complexes 1 and 10 of
41.5 and 37.2 h−1, respectively, at high concentrations of formate are
signiﬁcant improvements in catalytic activity compared to the Ru(II)
analogues (6.9 h−1), even for complex [(Cp*)Rh(TfEn)Cl] (10). This im-
provement in the maximum turnover frequency might be expected to
translate in signiﬁcant enhancements in antiproliferative activity to-
wards cancer cells when the complexes are used in combination with
high concentrations of formate.
We also demonstrated that some Rh(III) complexes, notably 1–5, 7
and 8, can catalyse the reduction of pyruvate to lactate using formate
as the hydride donor. Such reactionsmight occur in cells. However com-
plexes 6 and 9with very low TOFs are not effective catalysts. The trans-
fer hydrogenation reactions were shown to be greatly affected by the
chelating ligand and the capping Cpx ring. The catalytic activity of
ethylenediamine compounds (1–3) increases for extended Cpx rings,
while the bipyridine and phenanthroline compounds (4–9) show theopposite trend. Studies of competition reactions betweenNAD+andpy-
ruvate for reduction by formate catalysed by complex 4 suggested a
clear preference for the reduction of NAD+, although, some lactate
was still formed.
The antiproliferative activity of the Rh(III) complexes towards
A2780 human ovarian cancer cells increased by up to 50% (for complex
3) when administered in combination with formate. However, the im-
provement in the activity of these Rh(III) complexes induced by formate
is much lower than in the case of Ru(II) complexes. It is possible that
Rh(III) centres, being more reactive than Ru(II), are more easily
poisoned in the complicatedmixture of biomolecules present in culture
media and in cells.
Abbreviations
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